back to open calls
Health & Life Sciences
Project Size:
No upper funding limit


i4i Product Development Awards (PDA) support translational research and development of medical devices, in vitro diagnostics and high-impact patient-focused digital health technologies for ultimate NHS use. 


The research proposals may address any disease or health area, provided there is a clear unmet clinical need. There is no upper funding limit for Product Development Awards, but costs must be fully justified.



For all i4i awards the lead organisation must be based in England. The lead organisation may be any of the types of eligible organisation listed below. The following types of organisations are eligible for funding:


  • SMEs (including start-up or ‘spin-out’ companies)
  • NHS organisations (including NHS Trusts and NHS Foundation Trusts), and equivalent UK authorities
  • universities, research institutes and not-for-profit organisations


A collaboration of two or more of the above is eligible. Applications which involve partnerships between a university and its associated NHS Trust are considered eligible collaborations. If support for a clinical trial is requested, one of the partners must be an NHS organisation or other NHS service provider which has agreed to be the sponsor of the trial.


It is possible that an organisation outside England can request funding as a co-applicant, if an appropriate case is made.


Specialist services or expertise may be brought into the team through consultancy or sub-contract arrangements, however, appropriate justification must be provided. Sub-contractors may be based outside of England.



Funded activities include the following:


  • research and development of medical devices and in vitro diagnostic devices as defined by the relevant EU Regulations, across all areas of existing or emerging healthcare need
  • product development required to enable a technology for clinical use; work packages may comprise all aspects of prototyping and manufacturing, engineering and performance testing, intellectual property protection, and market analysis, business case development, etc
  • research and development of techniques or technologies from a different industry sector, which could have a potential impact if applied in a healthcare setting
  • feasibility studies if a technology from a sector other than health is being developed
  • studies to provide data relating to safety and effectiveness of a device, including first-in-man and pivotal clinical studies
  • health economic analyses and clinical utility studies, looking at a device’s real-life implementation and use
  • CE marking and other regulatory requirements, including work toward QMS development and the Clinical Evaluation Report
  • activities associated with the adoption of new technology
  • training associated with the implementation of new technology
  • digital health technologies that fall under Tier 3 of the NICE evidence framework, that are focused on patient outcomes and intended for ultimate NHS use


The i4i programme will not fund:

  • minor or incremental changes to technologies in current clinical use
  • projects involving small molecule drugs and biologics, including vaccines and gene therapies
  • projects involving stem cells, work on animals or animal tissue.
  • early stage or basic research.


Interested in this call? Book a free consultation with our team
Book a Consultation
+44 (0) 1925 506 100
Contact Us
Thank you! We will be in touch shortly.
Oops! Something went wrong while submitting the form.